These results suggest that higher risk of developing AD is associated with deregulation of ferroptosis-related proteins, and thus ferroptosis inhibitors may have a therapeutic potential in AD (Weiland et al., 2019)
Experimental data on animal models have suggested that GIP suppresses peripheral arterial remodeling, thus showing an anti-atherosclerotic activity, by acting on receptors in the heart and vessels." Outcomes of clinical trials The first clinical trial to test the clinical efficacy of TZP was the SURPASS program, a six-stage trial conducted on three separate cohorts Japanese (SURPASS-J), Asian-Pacific (SURPASS-AP), and the cardiovascular outcome trial (SURPASS-CVOT)
Tip: Rotate injection sites to minimize irritation
These changes include replacing -aminoisobutyric acid at position 8 and attaching a fatty acid at position 18
Safety/efficacy may differ in non-approved populations
Hara Y, McKeehan N, Dacks PA, Fillit HM